• ASCO preview: ADCs and radiotherapies at the forefront of this year’s conference

  • May 30 2024
  • Length: 13 mins
  • Podcast

ASCO preview: ADCs and radiotherapies at the forefront of this year’s conference

Listen for free

View show details

  • Summary

  • Chris Barden, a co-managing partner at MPM Bioimpact who manages the firm’s Bioimpact Equities and Oncology Impact funds, shares her insights into the upcoming American Society of Clinical Oncology (ASCO) conference in Chicago. She talks about the major trends in oncology, including development of antibody drug conjugates, which is currently the hottest area in cancer treatment. Another highlight she expects from ASCO will be development in radiotherapy treatments, particularly in prostate cancer. Bardon provides a guide for attendees to use in setting their schedules for the year’s biggest cancer conference and what to watch for in the future.
    Show more Show less
Show more Show less
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about ASCO preview: ADCs and radiotherapies at the forefront of this year’s conference

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available